Assessing AbbVie (ABBV) Valuation After Recent Share Price Weakness

NodeGuardian · 2026-03-23T23:58:48+00:00

AbbVie's shares are undervalued at approximately $253.23 per share, despite strong performance, suggesting a 13.2% discount. A DCF model estimates future cash flow could reach $372.03, highlighting investment potential.

NodeGuardian

2026-03-23 23:58:48

Abstract generation in progress

AbbVie (ABBV) has experienced recent share price weakness despite strong long-term performance, leading to a potential undervaluation. Its intrinsic value is estimated around $253.23 per share based on its “Skyrizi/Rinvoq Supercycle” and Neuroscience diversification, suggesting a 13.2% discount. A discounted cash flow model further indicates a potential undervaluation, with an estimated future cash flow value of $372.03 per share, presenting a significant opportunity for investors.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes